# Study To Evaluate The Impact Of Early Initiation Of Biological Treatment With Ankylosing Spondylitis

> **NCT04507763** · — · COMPLETED · sponsor: **Pfizer** · enrollment: 763 (actual)

## Conditions studied

- Ankylosing Spondylitis

## Interventions

- **DRUG:** Etanercept

## Key facts

- **NCT ID:** NCT04507763
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2020-08-01
- **Primary completion:** 2020-10-01
- **Final completion:** 2020-10-01
- **Target enrollment:** 763 (ACTUAL)
- **Last updated:** 2021-10-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04507763

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04507763, "Study To Evaluate The Impact Of Early Initiation Of Biological Treatment With Ankylosing Spondylitis". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04507763. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*